Eshaq A, Flanagan T, Ba Abbad A, Makarem Z, Bokir M, Alasheq A
Int J Mol Sci. 2025; 26(1.
PMID: 39795946
PMC: 11719825.
DOI: 10.3390/ijms26010088.
Pach J, Valido K, Belzer A, Leventhal J
Am J Clin Dermatol. 2024; 25(4):595-607.
PMID: 38767827
DOI: 10.1007/s40257-024-00866-z.
Xu Z, Wang Y, Jiang C, Wang Z, Cheng Y, Fan M
Mol Pain. 2024; 20:17448069241252384.
PMID: 38631843
PMC: 11069332.
DOI: 10.1177/17448069241252384.
Belzer A, Pach J, Valido K, Leventhal J
Am J Clin Dermatol. 2024; 25(3):435-445.
PMID: 38366030
DOI: 10.1007/s40257-024-00847-2.
Gu S, Dusza S, Quigley E, Haliasos H, Markova A, Marchetti M
Breast Cancer Res Treat. 2023; 203(2):271-280.
PMID: 37833451
PMC: 10787687.
DOI: 10.1007/s10549-023-07143-3.
Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors.
Teng Y, Yu S
Curr Oncol. 2023; 30(7):6805-6819.
PMID: 37504358
PMC: 10378098.
DOI: 10.3390/curroncol30070498.
Cutaneous manifestations associated with immune checkpoint inhibitors.
Watanabe T, Yamaguchi Y
Front Immunol. 2023; 14:1071983.
PMID: 36891313
PMC: 9986601.
DOI: 10.3389/fimmu.2023.1071983.
Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis.
Zhao F, Zhu J, Yu R, Shao T, Chen S, Zhang G
Sci Rep. 2022; 12(1):20038.
PMID: 36414662
PMC: 9681870.
DOI: 10.1038/s41598-022-24286-3.
Current quality of life assessment tools may not fully address dermatological adverse events from anti-cancer therapies.
Behroozian T, Fatima S, Finkelstein S, Kanee L, Bonomo P, Wolf J
Support Care Cancer. 2022; 30(12):9681-9685.
PMID: 36274078
DOI: 10.1007/s00520-022-07424-5.
Global research trends on precision cancer medicine-related rashes (2008-2021): A bibliographic study.
Zhao F, Yu R, Chen S, Zhao S, Sun L, Xu Z
Front Immunol. 2022; 13:1002034.
PMID: 36091077
PMC: 9458849.
DOI: 10.3389/fimmu.2022.1002034.
Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management.
Apalla Z, Rapoport B, Sibaud V
Int J Womens Dermatol. 2022; 7(5Part A):625-635.
PMID: 35005180
PMC: 8721136.
DOI: 10.1016/j.ijwd.2021.10.005.
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies.
Barrios D, Phillips G, Geisler A, Trelles S, Markova A, Noor S
Ann Oncol. 2021; 32(6):736-745.
PMID: 33667669
PMC: 9282165.
DOI: 10.1016/j.annonc.2021.02.016.
Causes of Pruritus in Patients Treated With Immune Checkpoint Inhibitors for Melanomas or Skin Carcinomas.
Salinas N, Nowak E, Etienne M, Legoupil D, Fouchard M, Brenaut E
Front Med (Lausanne). 2021; 8:632683.
PMID: 33634154
PMC: 7900003.
DOI: 10.3389/fmed.2021.632683.
Immune-related cutaneous adverse events due to checkpoint inhibitors.
Wang E, Kraehenbuehl L, Ketosugbo K, Kern J, Lacouture M, Leung D
Ann Allergy Asthma Immunol. 2021; 126(6):613-622.
PMID: 33609771
PMC: 8165024.
DOI: 10.1016/j.anai.2021.02.009.
Balancing Cancer Immunotherapy Efficacy and Toxicity.
Johnson D, Jakubovic B, Sibaud V, Sise M
J Allergy Clin Immunol Pract. 2020; 8(9):2898-2906.
PMID: 32599218
PMC: 7318967.
DOI: 10.1016/j.jaip.2020.06.028.
Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors.
Sun L, Arbesman J, Piliang M
Arch Dermatol Res. 2020; 313(1):1-10.
PMID: 32519001
DOI: 10.1007/s00403-020-02094-x.
Immune checkpoint inhibitor-related dermatologic adverse events.
Geisler A, Phillips G, Barrios D, Wu J, Leung D, Moy A
J Am Acad Dermatol. 2020; 83(5):1255-1268.
PMID: 32454097
PMC: 7572894.
DOI: 10.1016/j.jaad.2020.03.132.
Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.
Aso M, Toi Y, Sugisaka J, Aiba T, Kawana S, Saito R
Oncologist. 2020; 25(3):e536-e544.
PMID: 32162801
PMC: 7066688.
DOI: 10.1634/theoncologist.2019-0550.
Non-dermatological Challenges of Chronic Itch.
Kremer A, Mettang T, Weisshaar E
Acta Derm Venereol. 2020; 100(2):adv00025.
PMID: 31940045
PMC: 9128973.
DOI: 10.2340/00015555-3345.
Dermatologic conditions in women receiving systemic cancer therapy.
Ferreira M, Ramseier J, Leventhal J
Int J Womens Dermatol. 2020; 5(5):285-307.
PMID: 31909148
PMC: 6938835.
DOI: 10.1016/j.ijwd.2019.10.003.
